Fresenius SE & Co. KGaA (FRA:FRE) PT Set at €26.00 by Credit Suisse Group

Credit Suisse Group set a €26.00 ($27.96) target price on Fresenius SE & Co. KGaA (FRA:FRE – Get Rating) in a research report sent to investors on Tuesday, Borsen Zeitung reports.

FRE has been the topic of a number of other research reports. Warburg Research set a €34.00 ($36.56) price target on shares of Fresenius SE & Co. KGaA in a report on Friday, March 10th. UBS Group set a €32.50 ($34.95) price target on shares of Fresenius SE & Co. KGaA in a report on Tuesday, February 28th. Jefferies Financial Group set a €35.00 ($37.63) price target on shares of Fresenius SE & Co. KGaA in a report on Tuesday, February 21st. Deutsche Bank Aktiengesellschaft set a €22.00 ($23.66) price target on shares of Fresenius SE & Co. KGaA in a report on Thursday, March 9th. Finally, JPMorgan Chase & Co. set a €31.90 ($34.30) price target on shares of Fresenius SE & Co. KGaA in a report on Wednesday, February 22nd.

Fresenius SE & Co. KGaA Stock Performance

Shares of FRA FRE opened at €23.93 ($25.73) on Tuesday. Fresenius SE & Co. KGaA has a 1 year low of €60.16 ($64.69) and a 1 year high of €80.00 ($86.02). The firm’s 50 day moving average price is €27.13 and its 200 day moving average price is €25.16.

Fresenius SE & Co. KGaA Company Profile

(Get Rating)

Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.